Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer

<i>Background and Objectives</i>: In early-stage HER2-positive breast cancer, ado-trastuzumab emtansine (T-DM1) has been adopted as the preferred adjuvant approach for patients left with residual invasive disease despite neoadjuvant therapy. The influence of different neoadjuvant regimens on subsequ...

Cijeli opis

Bibliografski detalji

Glavni autori:	Ahmet Burak Agaoglu, Atike Pinar Erdogan, Ferhat Ekinci, Mustafa Sahbazlar, Guler Nur Tekustun, Ozgur Tanriverdi, Salih Tunbekici, Erdem Goker, Mehmet Sinan Akarca, Can Cangur, Taliha Guclu Kantar, Sedat Biter, Ertugrul Bayram, Gokhan Colak, Bilgin Demir, Hasan Basir, Vehbi Ercolak
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-11-01
Serija:	Medicina
Teme:	breast neoplasms HER2-positive post-neoadjuvant treatment outcomes real-world outcomes
Online pristup:	https://www.mdpi.com/1648-9144/61/11/1966
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!